There is no published head-to-head randomized trial comparing the bioequivalence, efficacy, or safety of compounded semaglutide or compounded tirzepatide against the FDA-approved brand-name products. Compounded GLP-1 medications are prepared by 503A pharmacies (patient-specific prescriptions) and 503B outsourcing facilities (bulk production) under FDA exemptions that do not require pre-market bioequivalence testing of the kind required for ANDA-approved generics. The papers ranked below represent the actual peer-reviewed evidence base: FAERS and EudraVigilance pharmacovigilance signals on adverse events linked specifically to compounded or counterfeit products, a poison-control case series documenting tenfold dosing errors, population-level overdose-reporting analyses, mass-spectrometry impurity characterization of mass-compounded tirzepatide/B12 and follow-on polypeptide drugs, the ADA and OMA position statements warning against routine compounded-GLP-1 use, a Colorado direct-to-consumer market characterization, a clinical-guidance review of compounded semaglutide for prescribers, and a 503A-versus-503B ethical and regulatory analysis. Readers should weigh these papers as documentation of safety signals, market behavior, and regulatory gaps — not as evidence that compounded products are or are not therapeutically equivalent to the brand reference.
Ranked papers
#1
McCall KL, et al. · Expert Opin Drug Saf · 2026
Primary endpoint: Disproportionality signals for compounded-GLP-1 adverse events in FAERS
McCall and colleagues queried the FDA Adverse Event Reporting System (FAERS) for reports naming compounded semaglutide or tirzepatide and applied disproportionality analysis (reporting odds ratio, proportional reporting ratio) against brand-name comparators. The compounded products generated elevated signals for medication errors, accidental overdose, dosing confusion, and injection-site reactions relative to brand semaglutide and tirzepatide. The study is not evidence of therapeutic inequivalence — FAERS cannot establish causation or denominators — but it is the most systematic pharmacovigilance signal-detection study on compounded GLP-1s published to date.
PMID 40285721 ↗DOI 10.1080/14740338.2025.2499670 ↗
#2
Jordan B, et al. · Expert Opin Drug Saf · 2026
Primary endpoint: Identification and quantification of a previously uncharacterized impurity in mass-compounded tirzepatide/B12 vials
Jordan and colleagues analyzed mass-compounded tirzepatide-plus-vitamin-B12 products sourced from multiple US 503A and 503B suppliers using LC-MS and orthogonal analytical techniques. They identified a previously uncharacterized impurity present across many lots — chemically distinct from the active tirzepatide peptide and from documented synthesis-related degradants — and discuss potential immunogenicity and unknown-toxicology implications. The paper is the strongest analytical-chemistry evidence published to date that mass-compounded GIP/GLP-1 products contain substances not present in the FDA-approved reference drug, and it is not equivalence evidence in either direction.
PMID 42010938 ↗DOI 10.1080/14740338.2026.2663185 ↗
#3
Hach M, et al. · Pharm Res · 2024
Primary endpoint: Physicochemical and aggregation properties of compounded vs reference GLP-1 polypeptide formulations
Hach and colleagues compared compounded and follow-on GLP-1 polypeptide preparations against the FDA-approved reference products using size-exclusion chromatography, mass spectrometry, and aggregation assays. They documented detectable differences in oligomer content, particulate burden, and impurity profiles in compounded samples versus the originator drug. The authors stop short of inferring clinical inequivalence — they explicitly note that bioavailability, efficacy, and immunogenicity require dedicated comparative trials — but the data show that the manufacturing-process gap between 503A/503B compounding and originator production is measurable at the molecule level.
PMID 39379664 ↗DOI 10.1007/s11095-024-03771-6 ↗
#4
Zinzi A, et al. · Front Pharmacol · 2026
Primary endpoint: Disproportionality signals for counterfeit-flagged semaglutide adverse events in EudraVigilance
Zinzi and colleagues extracted adverse event reports from EudraVigilance — the European Medicines Agency pharmacovigilance database — that flagged the implicated semaglutide product as counterfeit or non-genuine. Disproportionality analyses identified excess signals for hypoglycemia, dosing errors, and severe gastrointestinal events compared with reference semaglutide. The European counterpart to the US FAERS work, the paper is one of only two published analyses isolating non-genuine-supply adverse events from authentic-supply background and reinforces that the counterfeit-versus-brand safety gap is real-world detectable.
PMID 42137313 ↗DOI 10.3389/fphar.2026.1805842 ↗
#5
Lambson JE, et al. · J Am Pharm Assoc (2003) · 2023
Primary endpoint: Case-series description of compounded semaglutide dosing-error calls
Lambson and colleagues reviewed compounded-semaglutide cases reported to a regional poison control center and documented a recurring pattern: patients receiving multi-dose vials drew up doses in 'units' on insulin syringes rather than the prescribed milligrams, producing tenfold and twentyfold overdoses. Several patients required emergency department care for protracted vomiting and dehydration. The case series is small and uncontrolled but is the foundational clinical paper documenting the syringe-vial-versus-prefilled-pen dosing-error hazard that distinguishes compounded multi-dose vials from FDA-approved Wegovy and Ozempic pens.
PMID 37392810 ↗DOI 10.1016/j.japh.2023.06.017 ↗
#6
McIntyre RS, et al. · Expert Opin Drug Saf · 2026
Primary endpoint: Trend in accidental GLP-1 overdose reports across population-level pharmacovigilance and poison-control data
McIntyre and colleagues combined FAERS, poison-control, and adjacent surveillance datasets to track accidental GLP-1 overdose reports across calendar years coinciding with the rise of compounded-product distribution. They documented a sharp absolute and proportional increase in accidental-overdose case volume, with the surge concentrated in compounded multi-dose-vial dispensings rather than in branded prefilled-pen dispensings. The paper does not isolate compounded-versus-brand causation but provides the strongest population-level signal that the dosing-error pattern Lambson described in a single poison center generalizes nationally.
PMID 39552465 ↗DOI 10.1080/14740338.2024.2430306 ↗
#7
Neumiller JJ, et al. · Diabetes Care · 2025
Primary endpoint: Position statement on clinical use of compounded GLP-1 and GIP/GLP-1 products
Neumiller and the American Diabetes Association compounding working group reviewed available evidence on compounded GLP-1 and dual GIP/GLP-1 products and issued the ADA's formal position: compounded products should be used only when the FDA-approved drug is unavailable due to documented shortage and when prescribed through a state-licensed 503A pharmacy with a patient-specific prescription. The statement catalogues documented safety signals (dosing errors, salt-form substitution, impurity reports) and the absence of any bioequivalence or comparative-efficacy data. It is the most authoritative US specialty-society guidance on the topic.
PMID 39620926 ↗DOI 10.2337/dci24-0091 ↗
#8
Liu G, et al. · Am J Manag Care · 2025
Primary endpoint: Clinical-guidance review for prescribers on compounded semaglutide use
Liu and colleagues review the legal, regulatory, and clinical considerations facing prescribers asked about compounded semaglutide. The review summarizes the FDA shortage-list framework, the 503A versus 503B distinction, the absence of pre-market bioequivalence testing, documented salt-form and impurity concerns, and the patient-counseling points that should accompany any compounded-product prescription. Written for managed-care and primary-care audiences, the paper is the most practical clinician-facing guidance document published on the topic and pairs naturally with the ADA position statement for shared decision-making conversations.
PMID 40966636 ↗DOI 10.37765/ajmc.2025.89787 ↗
#9
DiStefano MJ, et al. · J Pharm Policy Pract · 2025
Primary endpoint: Cross-sectional characterization of direct-to-consumer compounded-GLP-1 sellers in Colorado
DiStefano and colleagues conducted a cross-sectional audit of direct-to-consumer telehealth and pharmacy websites selling compounded semaglutide and tirzepatide to Colorado residents. They catalogued pricing, dosing instructions, clinician-oversight claims, salt-form disclosures, and source-pharmacy licensure status. The study documents heterogeneous and frequently incomplete disclosure of compounded status, salt form (acetate vs base), and ingredient sourcing — the kind of market-level information that bioequivalence trials cannot capture but that determines what patients actually receive. The paper is the most rigorous US state-level market-conduct study on compounded GLP-1 sellers.
PMID 39776466 ↗DOI 10.1080/20523211.2024.2441220 ↗
#10
Asbill HR, et al. · Int J Pharm Compd · 2026
Primary endpoint: Regulatory and ethical analysis of 503A versus 503B sourcing during the GLP-1 shortage period
Asbill and colleagues frame the FDA's 2022-2024 semaglutide and tirzepatide shortage designations as a regulatory case study and contrast the rules, oversight, and patient-safety implications of 503A (patient-specific) versus 503B (outsourcing-facility) compounding. The paper walks through the FDA's 2024-2025 shortage-resolution timeline, the resulting cease-compounding deadlines, and the ethical obligations on prescribers when shifting patients back to brand products. It is the clearest regulatory-framework reference for understanding why the legal status of a compounded GLP-1 prescription has changed over a single 18-month window.
PMID 42143782 ↗
About this list
We curate ranked, citation-anchored PubMed paper lists for the most-searched questions in obesity medicine. Every citation on this page was checked against PubMed on 2026-05-28. Each paper card links directly to PubMed and to ClinicalTrials.gov where applicable.
Browse our full index of research lists or our long-form research articles.